April 13, 2026 |
Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.

Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success – including market analysis, sales teams, MSLs, training, launch meeting support, congress experiences, and product value demonstration.  Â
Our client is a US biotechnology company that specializes in developing therapies for complex and chronic conditions. For many years, the firm has been working on what’s become the first new FDA-approved therapy of its kind in almost two decades. Â
Our client’s landmark product is an easy-to-use therapy that allows for rapid absorption and targets various receptors. In clinical trials, the treatment was shown to significantly reduce pain.Â
Primarily, the client needed a commercialization partner to rapidly set up a large, flexible nationwide sales team ready for the product launch in October 2025.Â
Read the full case study here.
This content was provided by Inizio
Latest Content from Inizio
We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.
A few key considerations for conducting healthcare market research in the Gulf
Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a…
Live webinar: Thursday 30th March 10:00 EDT / 15:00 BST / 16:00 CEST
Published in eyeforpharma February 2017 by Marc Yates
Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research…
Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and…
SLE is a progressive and debilitating disease which affects 5 million people worldwide.
Pegasus, an Ashfield company, part of UDG Healthcare plc, is proud to announce the launch of its new propriety model for planning in health – CHANGE – which was developed…
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
